Business
BridgeBio is a commercial-stage biopharmaceutical company organized around a portfolio model for medicines targeting genetic diseases.
BridgeBio revenue more than doubled and free cash flow improved, but losses widened, debt rose, and forensic screens were weak.
The read at a glance✓ Audited against SEC data
- Business mix — Genetic-disease biopharmaNote
- Revenue — Revenue rose 126.3%OK
- Losses — Net loss widened to $732.9MWatch
- Cash — Free cash flow improved but stayed negativeNote
- Balance sheet — Debt rose to $2.01BWatch
- Insiders — 0 purchases / 46 salesWatch
- Accounting — Altman-Z distress; Beneish-M flag; earnings-quality greyWatch
Where the revenue comes from
Fiscal 2025, as BridgeBio Pharma, Inc. reports it. History and quarterly detail are in the app.
- Net product revenue$362.4M
- License and services revenue$128.3M
- Cost of license, services, and royalty revenue$93.8M
- Royalty revenue$11.4M
Leadership changes
From BridgeBio Pharma, Inc.'s own filings, the day they're filed.
- Randal W. Scott · member · departureeff. 2026-06-22
- Neil Kumar · Chief Operating Officer · departureeff. 2024-07-23
Latest filings
- 8-K · Company announcement2026-08-31
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-07-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BridgeBio Pharma, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.